modes of transmission. See
transmission modes
Mohs’ micrographic surgery 1:176
mold 2:271, 279, 327; 4: 34
molecularly targeted therapies
2:368, 384, 384, 384 , 384, 384 t,
397
molecular medicine 4:4, 28, 111
monoamine oxidase (MAO) 3:361;
4:97, 107
monoclonal antibodies (MAbs)
2:283, 283 t;3: 252
cancer treatment options and
decisions 2: 372
DMARDs 2: 258
graft vs. host disease 2: 264
hypersensitivity reaction 2: 270
immune system 2: 238
immunotherapy 2: 277
oncogenes 2: 384
TNFs 2: 297
tumor suppressor genes 2: 397
monocyte 2:157
granulocyte 2: 139
human ehrlichiosis 2: 335
immune response 2: 272
leukocyte 2:119–120
lymph 2: 120
lymphocyte 2: 152
macrophage 2:282
monokines 2: 283
phagocytosis 2: 162
monokines 2:283
mononuclear phagocyte system
2:162, 167, 282, 283–284
mononucleosis, infectious 2:275,
303, 323, 344–345
monosaccharide 3:4, 128; 4: 191
monosomy 4:117, 128
monovision 1:83, 109
morbid obesity 4:284, 302
morning sickness 3:305–306,322;
4: 70
morphine 1:363, 377
dependence 4: 330
drugs 4: 145
fentanyl 4: 334
heroin 4: 338
methadone 4: 342
opiates 4: 347
substance abuse 4: 311
mosaic autosomal trisomy 4:114,
122, 136
mosaicism 4:134–135
mosquito bites 2:322, 324, 342
motor nerves 1:246, 247t, 252
motor neuron disease 1:265, 297.
See alsoamyotrophic lateral
sclerosis
motor vehicle accidents 4:2, 5, 40,
312, 316, 378–379
mouth 1:35
bronchoscopy 2: 197
buprenorphine 4: 325
candidiasis 2: 315
canker sore 1:14
cold sore 1:17–18
digestive enzymes 3: 35
gastrointestinal system 3:1, 3
halitosis 1:26
herpes simplex 2: 332
HPV 2: 336
leukoplakia 1:32
myoclonus 1: 266
normal flora 2: 346
oral hygiene 1: 39
salivary glands 1:49
teeth 1:358
temporomandibular disorders
1: 359
thrush 1:57–58
tobacco 4: 353
tobacco use other than smoking
4: 306
mucocutaneous lymph node
syndrome. SeeKawasaki disease
mucosa 2:287–288, 319
mucosa-associated lymphoid tissue
(MALT) 2:235, 236, 239, 242,
275 , 284,289, 296, 324
mucous membranes 1:49, 182;
2:283, 294–295, 306, 349
mucus 1:47, 51; 2:199, 202, 231,
233, 287
multiple chemical sensitivity
syndrome 2:190, 223, 284–285
multiple-drug-resistant infections
4:147, 160
multiple endocrine neoplasia
(MEN) 3: 94 , 151–152, 156
multiple myeloma 2:138, 148, 152,
157–160, 158 t,372, 384
multiple sclerosis 1:263–265, 264 t,
269
multiple trauma 4:49, 367, 377,
378 , 379,379, 380
mumps 2:345
muscle 1:336–337
aging and musculoskeletal
changes 1:299–300
bursa 1:311–312
bursitis 1: 312contracture 1:319
cramp 1:319
dystonia 1:320
fibromyalgia 1:321–322
hernia 1:325–326
Langer’s lines 4: 265
lean muscle mass 4: 297
lipoma 1: 333
musculoskeletal system
1:293–294
myasthenia gravis 1: 339
myopathy 1:339–340
myotonia 1:340
polymyositis 1:350
rhabdomyoma 1: 353
spasm 1:356
spastic cerebral palsy 1:238–239
sprains and strains 1: 355
strength 4: 232
tendon 1: 359
tension headache 1: 373
torticollis 1: 360
triceps skinfold 4: 307
trigger-point injection 1: 385
weak ankles 4: 237
muscle cramp 4:50, 217, 374, 375,
381
muscle mass 4:77, 215, 321, 336
muscle relaxant medications 1: 75 ,
337, 337 t;4: 324
muscle spasm. Seespasm
muscle strength 4:211, 228, 229
muscle tone 3:93, 245
muscular dystrophy 1: 295 ,
337–339, 338 t;4:135, 139, 140,
163
musculoskeletal system 1:290–360,
291 , 292
biomechanics of movement
1: 294
bone 1:307–309
breakthrough research and
treatment advances
1:295–296
chiropractic 4: 63
functions of 1: 293
health and disorders of
1:294–295, 295t
joint 1:328
joints 1: 294
ligament 1:333
muscle 1:336–337
muscles 1:293–294
obesity and health 4: 301
overview 1:290–296
resistance exercise 4: 230Index 489